INOVIO Announces Further Reorganization, Continues Focus on Promising DNA Candidates

  • INOVIO Pharmaceuticals INO announced a strategic reorganization expected to provide annual savings of approximately $4.3 million and includes an 11% reduction of full-time employees following the previously announced discontinuation of clinical development programs in late 2022. 
  • In October, the company discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine.
  • These and other strategic measures redirect resources to advance key programs, including INOVIO's product candidate INO-3107 for Recurrent Respiratory Papillomatosis (RRP).
  • INOVIO expects to incur a one-time restructuring charge of approximately $1.1 million in the first quarter of 2023. 
  • INOVIO's lead programs include its treatments for HPV-associated diseases, such as INO-3107 for RRP and VGX-3100 for cervical high-grade squamous intraepithelial lesions (HSIL). 
  • Data readouts for INOVIO's Phase 3 REVEAL2 trial for VGX-3100 and the second cohort from the Phase 1/2 trial for INO-3107 are expected in the first quarter of 2023.
  • In July, Inovio implemented a corporate reorganization, cutting its full-time workforce by 18% and 86% for contractors and extending its cash runway into Q3 of 2024
  • Price Action: INO shares are up 2.76% at $1.68 on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!